Oncology + Eternal = Oncternal

We are committed to advancing novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Our scientific approach focuses on promising, yet untapped biological pathways implicated in cancer generation or progression.

Oncology + Eternal = Oncternal

We are committed to advancing novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Our scientific approach focuses on promising, yet untapped biological pathways implicated in cancer generation or progression.

Oncology + Eternal = Oncternal

We are committed to advancing novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Our scientific approach focuses on promising, yet untapped biological pathways implicated in cancer generation or progression.

Welcome to Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments to treat hematological malignancies and prostate cancer across multiple modalities.

We are enrolling patients:

With Relapsed or Refractory B-Cell Malignancies for a Phase 1/2 study of ONCT-808, our ROR1-Targeting Autologous Cell Therapy (NCT05588440)

AND

With Relapsed or Refractory Metastatic Castration Resistant Prostate Cancer for a Phase 1/2 study of ONCT-534, our Dual-Action Androgen Receptor Inhibitor (NCT05917470)